- Home
- PETZ vs KPRX Comparison
PETZ vs KPRX Comparison
Compare PETZ & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- KPRX
- Stock Information
- Founded
- PETZ 2002
- KPRX 1998
- Country
- PETZ China
- KPRX United States
- Employees
- PETZ N/A
- KPRX N/A
- Industry
- PETZ Steel/Iron Ore
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PETZ Industrials
- KPRX Health Care
- Exchange
- PETZ Nasdaq
- KPRX Nasdaq
- Market Cap
- PETZ 9.3M
- KPRX 9.2M
- IPO Year
- PETZ 2017
- KPRX N/A
- Fundamental
- Price
- PETZ $1.09
- KPRX $2.75
- Analyst Decision
- PETZ
- KPRX Strong Buy
- Analyst Count
- PETZ 0
- KPRX 1
- Target Price
- PETZ N/A
- KPRX $10.00
- AVG Volume (30 Days)
- PETZ 246.3K
- KPRX 35.6K
- Earning Date
- PETZ 04-28-2025
- KPRX 11-07-2025
- Dividend Yield
- PETZ N/A
- KPRX N/A
- EPS Growth
- PETZ N/A
- KPRX N/A
- EPS
- PETZ 0.26
- KPRX N/A
- Revenue
- PETZ $563,726.00
- KPRX N/A
- Revenue This Year
- PETZ N/A
- KPRX N/A
- Revenue Next Year
- PETZ N/A
- KPRX N/A
- P/E Ratio
- PETZ $5.51
- KPRX N/A
- Revenue Growth
- PETZ 74664.72
- KPRX N/A
- 52 Week Low
- PETZ $0.65
- KPRX $2.25
- 52 Week High
- PETZ $1.74
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- PETZ 49.23
- KPRX 55.26
- Support Level
- PETZ $1.06
- KPRX $2.67
- Resistance Level
- PETZ $1.19
- KPRX $2.89
- Average True Range (ATR)
- PETZ 0.06
- KPRX 0.11
- MACD
- PETZ -0.00
- KPRX 0.02
- Stochastic Oscillator
- PETZ 23.33
- KPRX 70.26
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.